Please login to the form below

Not currently logged in
Email:
Password:

pharma pricing

This page shows the latest pharma pricing news and features for those working in and with pharma, biotech and healthcare.

J&J earnings top expectations, but feels the squeeze in US

J&J earnings top expectations, but feels the squeeze in US

J&J chalked up the sales decline to a competitive US market, thrown into turmoil  last year by Trump’s drug pricing agenda. ... This resulted in many pharma giants, including Novartis and Pfizer, freezing their drug prices and prompting further

Latest news

More from news
Approximately 2 fully matching, plus 88 partially matching documents found.

Latest Intelligence

  • The UK’s new five-year pricing agreement The UK’s new five-year pricing agreement

    The UK has a new five-year Voluntary Pricing and Access Scheme (VPAS) for branded medicines, which came into force on 1 January 2019. ... The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt.

  • Comment: the new UK pricing deal – welcome news, but lessons to be learned Comment: the new UK pricing deal – welcome news, but lessons to be learned

    Leslie Galloway, chairman of EMIG reflects on the new UK government-pharma industry pricing agreement. ... Leslie Galloway, chairman, EMIG. The deal is done. After undoubtedly tense negotiations, the heads of terms for the new Voluntary Scheme for

  • Patient outcomes in practice: delivering value that transforms lives Patient outcomes in practice: delivering value that transforms lives

    Providers, payers and manufacturers all have a role in achieving value, with increasing ethical pressure on drug pricing and resultant innovative, outcomes-based pricing models. ... This should be the goal of pharma and the ‘value-add’ packages

  • No incentive for a cure No incentive for a cure

    general negativity around pharma pricing - could mean a backward step for innovation. ... What is realistic? What would incentivise pharma? Get involved in the debate on.

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Fewer NCEs coming through. Politics and pricing certainly had an impact, with the US backlash against aggressive pharma pricing following Mylan's EpiPen debacle, itself coming on the heels of the ... Digital health is expected to be a major investment

More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics